DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Metastatic Castration-Resistant Prostate Cancer, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market

• The market size for Metastatic Castration-Resistant Prostate Cancer in the leading markets is expected to grow significantly by 2036.

• DelveInsight estimates that the total mCRPC market in the 7MM was valued at approximately USD 8 billion in 2025.

• In 2025, the 7MM accounted for approximately 7.7 million prevalent cases of prostate cancer, which are expected to increase during the forecast period.

• Around 43% of all metastatic prostate cancer cases are attributed to mCRPC.

• The United States accounted for the highest mCRPC market size in the 7MM in 2025 compared with EU4, the United Kingdom, and Japan.

• Prostate cancer is the third most prevalent cancer in the United States and the fourth most common cancer worldwide.

• The number of prostate cancer cases in Japan has increased by nearly 1.8 times over the last decade.

• Leading mCRPC companies, such as Merck and Orion, Pfizer, Curium, Exelixis, Tavanta Therapeutics, AstraZeneca, Telix International, Lantheus, Eli Lilly/POINT Biopharma, MacroGenics, Promontory Therapeutics, and others, are developing innovative therapies that are expected to enter the market during the forecast period.

• The promising mCRPC therapies in clinical development include Opevesostat, Mevrometostat, CABOMETYX, 177Lu-PSMA-I&T, 177Lu-PNT2002, TAVT-45, ARV-766, FPI-2265, PT-112, KPG-121, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market

Key Factors Driving the Metastatic Castration-Resistant Prostate Cancer Market

Increasing Prevalence of Prostate Cancer and Aging Population: Increasing life expectancy and the growing burden of prostate cancer are resulting in a larger pool of patients progressing to advanced and castration-resistant disease stages, thereby driving demand for innovative therapies.

Growing Adoption of Precision Medicine and Biomarker-Based Therapies: Advances in molecular diagnostics and genomic profiling are enabling more personalized treatment approaches, accelerating the use of PARP inhibitors, targeted therapies, and biomarker-driven treatment strategies.

Rising Utilization of Radioligand Therapies: The approval and commercial success of PLUVICTO have highlighted the potential of radioligand therapies, encouraging the development of next-generation PSMA-targeted radiopharmaceuticals that are expected to reshape the treatment landscape.

Strong Emerging Pipeline Activity: The mCRPC pipeline remains highly active with novel mechanisms including CYP11A1 inhibitors, EZH2 inhibitors, PROTAC degraders, antibody-drug conjugates, radiopharmaceuticals, and CRBN E3 ligase modulators advancing through clinical development.

Metastatic Castration-Resistant Prostate Cancer Competitive Landscape

Current treatment options for mCRPC include androgen receptor inhibitors, PARP inhibitors, chemotherapy, radiopharmaceuticals, immunotherapies, and supportive therapies. Key marketed products include XTANDI, LYNPARZA, AKEEGA, TALZENNA, PLUVICTO, XOFIGO, and JEVTANA.

Several mCRPC drugs in development include Opevesostat (Merck and Orion), Mevrometostat (Pfizer), CABOMETYX (Exelixis), 177Lu-PSMA-I&T (Curium), 177Lu-PNT2002 (Lantheus/Eli Lilly-POINT Biopharma), TAVT-45 (Tavanta Therapeutics), ARV-766 (Arvinas/Novartis), FPI-2265 (AstraZeneca), PT-112 (Promontory Therapeutics), and KPG-121.

These candidates target diverse mechanisms including CYP11A1 inhibition, EZH2 inhibition, androgen receptor degradation, PSMA-targeted radiotherapy, CRBN E3 ligase modulation, and immune-mediated anti-tumor activity, aiming to improve outcomes and overcome treatment resistance in advanced prostate cancer.

Discover more about therapies set to grab major Metastatic Castration-Resistant Prostate Cancer market share @ Metastatic Castration-Resistant Prostate Cancer Treatment Landscape

Recent Developments in the Metastatic Castration-Resistant Prostate Cancer Market

• In August 2025, K36 Therapeutics announced that the US FDA cleared the Investigational New Drug (IND) application for KTX-2001 in patients with mCRPC.

• In June 2025, Pfizer announced FDA approval of updated labeling for TALZENNA in combination with XTANDI, including final overall survival data for HRR gene-mutated mCRPC patients.

• In April 2025, AstraZeneca discontinued the CAPItello-280 Phase III study evaluating TRUQAP in mCRPC after determining the study was unlikely to meet its primary endpoints.

• In March 2025, Novartis announced FDA approval of PLUVICTO for patients with PSMA-positive mCRPC who have received androgen receptor pathway inhibitor therapy.

• In November 2024, Curium announced that its Phase III ECLIPSE trial evaluating 177Lu-PSMA-I&T met its primary endpoint in patients with mCRPC.

What is Metastatic Castration-Resistant Prostate Cancer?

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy and castrate levels of testosterone. Patients experience disease progression through rising prostate-specific antigen levels, radiographic progression, or worsening clinical symptoms. Although multiple treatment options are available, mCRPC remains a challenging and life-threatening condition requiring continuous therapeutic innovation.

Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmentation

The Metastatic Castration-Resistant Prostate Cancer epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The mCRPC market report provides epidemiological analysis for the study period 2022–2036 segmented into:

• Total Prevalent Cases of Prostate Cancer

• Five-year Prevalent Cases of Prostate Cancer

• Age-specific Cases of Prostate Cancer

• Clinical Stage-specific Cases of Prostate Cancer

• Metastatic Cases of Prostate Cancer

• Total Prevalent Cases of mCRPC

• Drug-treated Cases of mCRPC

Scope of the Metastatic Castration-Resistant Prostate Cancer Market Report

• Therapeutic Assessment: Metastatic Castration-Resistant Prostate Cancer current marketed and emerging therapies

• Market Dynamics: Key Market Forecast Assumptions of Emerging mCRPC Drugs and Market Outlook

• Key Companies: Merck and Orion, Pfizer, Curium, Exelixis, Tavanta Therapeutics, AstraZeneca, Telix International, Lantheus, Eli Lilly/POINT Biopharma, MacroGenics, Promontory Therapeutics, and others

• Key Therapies: Opevesostat, Mevrometostat, CABOMETYX, 177Lu-PSMA-I&T, 177Lu-PNT2002, TAVT-45, ARV-766, FPI-2265, PT-112, XTANDI, LYNPARZA, AKEEGA, TALZENNA, PLUVICTO, and others

• Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Market Access and Reimbursement

To know more about Metastatic Castration-Resistant Prostate Cancer companies working in the treatment market, visit @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

• Metastatic Castration-Resistant Prostate Cancer Market Report Introduction

• Executive Summary for Metastatic Castration-Resistant Prostate Cancer

• SWOT Analysis of Metastatic Castration-Resistant Prostate Cancer

• Metastatic Castration-Resistant Prostate Cancer Patient Share (%) Overview at a Glance

• Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance

• Metastatic Castration-Resistant Prostate Cancer Background and Overview

• Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population

• Country-Specific Patient Population of Metastatic Castration-Resistant Prostate Cancer

• Metastatic Castration-Resistant Prostate Cancer Current Treatment and Medical Practices

• Metastatic Castration-Resistant Prostate Cancer Unmet Needs

• Metastatic Castration-Resistant Prostate Cancer Emerging Therapies

• Metastatic Castration-Resistant Prostate Cancer Market Outlook

• Country-Wise Metastatic Castration-Resistant Prostate Cancer Market Analysis (2022–2036)

• Metastatic Castration-Resistant Prostate Cancer Market Access and Reimbursement of Therapies

• Metastatic Castration-Resistant Prostate Cancer Market Drivers

• Metastatic Castration-Resistant Prostate Cancer Market Barriers

• Metastatic Castration-Resistant Prostate Cancer Appendix

• Metastatic Castration-Resistant Prostate Cancer Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/